Fig. 2

Mutant A152T tau accumulates in the soluble fraction. a and b Biochemical fractionation into sarkosyl-insoluble P3 fraction (a) and soluble S1 fraction (b) indicate hyperphosphorylated tau remains soluble in Tau^A152T-AAV mice and becomes insoluble in Tau^P301L-AAV mice. c Quantitation of CP13 levels in the S1 fraction normalized to GAPDH as a control for protein loading (t = 7.86, p < 0.0001). d Human tau mRNA levels are equal between Tau^P301L-AAV and Tau^A152T-AAV mice (t = 0.35, p = 0.73). e Human tau protein levels in S1 fraction measured by MSD immunoassay are significantly lower in Tau^A152T-AAV compared to Tau^P301L-AAV mice (t = 3.382, p = 0.0028). f Human tau levels in S2 fraction are also reduced in Tau^A152T-AAV relative to Tau^P301L-AAV mice (t = 5.835, p < 0.0001). g Minimal human tau is detected in the P3 fraction in Tau^A152T-AAV mice (t = 4.549, p = 0.0002). **p < 0.005, ***p < 0.001, ****p < 0.0001